CLINICAL_TRIALS
trial_result
· 2015-03-03
Clinical Trial Update: Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid [Phase 2, Phase 3]
Summary
Phase 2/3 clinical trial update examining genetic predictors of raltegravir penetration into cerebrospinal fluid in HIV infection. Results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Vanderbilt University | Conditions: HIV Infections | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2015-03-03